FilingFirehose · custom report

SGMO — SANGAMO THERAPEUTICS, INC

SEC filings analysis · 4 filings reviewed (last 12 months) · generated 2026-06-29 14:19 UTC

Executive summary

Sangamo Therapeutics filed four 8-K forms over the past 12 months, with the most significant activity occurring in June 2026 involving a material definitive agreement (item 1.01), costs associated with exit or disposal activities (item 2.03), and creation of a direct financial obligation (item 2.05). In May 2026, the company also reported a material agreement (item 2.02). One April 2026 filing shows a potential discrepancy between stated items (3.01 – changes in bylaws) and detected content, though the precise nature of these amendments remains unclear from the data provided.

Dilution risk 2/5

The filing data does not reveal active equity issuances, ATM offerings, or explicit stock-based compensation acceleration. However, the June 2026 filings reference creation of direct financial obligations (item 2.05) and a material definitive agreement (item 1.01), which could result in share issuance depending on their terms. The April 2026 bylaw amendment (item 3.01) could relate to authorization changes, but without access to the full amendment text, dilution risk cannot be quantified. Dilution is not an immediate or observed primary concern based on the limited evidence.

Item 2.05 (Costs associated with exit or disposal) filed 2026-06-23, suggesting potential restructuring
Item 1.01 (Material definitive agreement) filed 2026-06-23, terms unknown
Item 3.01 (Changes in bylaws) filed 2026-04-29, content not disclosed

Notable filings (4)

2026-06-23 8-K	Material definitive agreement, business combination or asset disposition, and direct financial obligation disclosed. · filing The company entered into a significant agreement with potential M&A, restructuring, or major transaction components. The concurrent disclosure of exit/disposal costs (2.03) and a direct financial obligation (2.05) suggests a complex transaction with cash impact and possible organizational changes.
2026-06-23 8-K	Financial statements and exhibits filed as Item 9.01 (Exhibits). · filing Material exhibits were attached; likely supporting documents for the earlier June 23 transaction disclosures (1.01, 1.03, 2.03, 2.05).
2026-05-14 8-K	Material definitive agreement (2.02) and financial statements/exhibits (9.01) reported. · filing A material agreement was executed and supporting documents were filed. This may represent a partnership, licensing deal, or other contractual commitment with financial significance.
2026-04-29 8-K	Changes in bylaws (Item 3.01) disclosed; discrepancy detected between filer-stated item and buried content. · filing Bylaws were amended, but the filer reported item 3.01 while detection algorithms flagged 8.01 (Other Events). This suggests either a filing error or material content classified atypically. The nature of the bylaw change (e.g., board composition, voting rights, share authorization) is not evident from the data.

Financing activity

No ATM offerings, shelf registrations, or explicit capital raises are evident in the four 8-K filings analyzed. However, the May 2026 and June 2026 disclosures of material definitive agreements and direct financial obligations (item 2.05) may involve future financing commitments or debt issuance tied to transaction terms. Without access to the full agreement text or prospectuses, the magnitude and type of financing cannot be quantified.

Risk signals

Item 2.03 (Costs associated with exit or disposal activities) filed June 23, 2026 signals potential workforce reduction, facility closures, or program discontinuation—a sign of strategic contraction or operational stress.
Item 2.05 (Costs associated with exit or disposal) and Item 1.01 (Material definitive agreement) filed in close succession suggest a complex transaction with contingent or long-term cash obligations; terms and financial impact are not yet disclosed.
April 2026 bylaw amendment shows a discrepancy between filer-stated item (3.01) and detected content (8.01), indicating either a classification error or atypical treatment of governance changes. Investors should review the full amendment when available.
Two separate material definitive agreements filed within 30 days (May 14 and June 23) suggest accelerated M&A or partnership activity; the business rationale and strategic alignment should be examined closely.
No financing activity (equity or debt shelf) is evident, yet the company is incurring exit/disposal costs and assuming direct financial obligations, raising questions about cash runway and balance sheet adequacy.

Bottom line

Sangamo Therapeutics has reported a series of significant corporate actions in the past 12 months centered on material agreements and restructuring costs, but the SEC filings data does not provide sufficient detail to assess strategic direction, financial impact, or long-term viability. Investors should obtain and review the full 8-K exhibits, amended bylaws, and definitive agreement summaries to understand the nature of the May and June 2026 transactions, the magnitude of exit costs, and any associated dilution or debt obligations. The absence of transparent financing disclosure coupled with costs tied to disposals warrants heightened scrutiny of management guidance and cash flow projections.

View this report online